Rui Moreira

List of Publications by Year
in descending order

172 papers	5,514 citations	108046 37 h-index	129628 63 g-index
191 all docs	191 docs citations	191 times ranked	7561 citing authors

#	Article	IF	Citations
1	Indole-Containing Pyrazino[2,1-b]quinazoline-3,6-diones Active against Plasmodium and Trypanosomatids. ACS Medicinal Chemistry Letters, 2022, 13, 225-235.	1.3	11
2	Tandem Thioâ€Michael Addition/Remote Lactone Activation of 5â€Hydroxymethylfurfuralâ€Derived Î´â€Lactoneâ€Fused Cyclopentenones. ChemSusChem, 2022, , e202102204.	3.6	2
3	Designer Cathinones N-Ethylhexedrone and Buphedrone Show Different In Vitro Neurotoxicity and Mice Behaviour Impairment. Neurotoxicity Research, 2021, 39, 392-412.	1.3	6
4	Recovery of Depleted miR-146a in ALS Cortical Astrocytes Reverts Cell Aberrancies and Prevents Paracrine Pathogenicity on Microglia and Motor Neurons. Frontiers in Cell and Developmental Biology, 2021, 9, 634355.	1.8	26
5	MO1046DOPING POLYSULFONE DIALYSIS MEMBRANES WITH HUMAN NEUTROPHIL ELASTASE INHIBITORS - A PILOT STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
6	Discovery of a Necroptosis Inhibitor Improving Dopaminergic Neuronal Loss after MPTP Exposure in Mice. International Journal of Molecular Sciences, 2021, 22, 5289.	1.8	8
7	Biological Evaluation and Mechanistic Studies of Quinolin-(1 H)-Imines as a New Chemotype against Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0151320.	1.4	1
8	Augmenting Adaptive Machine Learning with Kinetic Modeling for Reaction Optimization. Journal of Organic Chemistry, 2021, 86, 14192-14198.	1.7	9
9	Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry, 2021, 5, 726-749.	13.8	439
10	Metabolism of N-ethylhexedrone and buphedrone: An in vivo study in mice using HPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1159, 122340.	1.2	7
11	Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds. International Journal of Molecular Sciences, 2020, 21, 8854.	1.8	9
12	Half-Sandwich Cyclopentadienylruthenium(II) Complexes: A New Antimalarial Chemotype. Inorganic Chemistry, 2020, 59, 12722-12732.	1.9	7
13	3-Oxo-Î²-sultam as a Sulfonylating Chemotype for Inhibition of Serine Hydrolases and Activity-Based Protein Profiling. ACS Chemical Biology, 2020, 15, 878-883.	1.6	11
14	Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition. Cell Death Discovery, 2020, 6, 6.	2.0	13
15	Azaaurones as Potent Antimycobacterial Agents Active against MDRâ€and XDRâ€TB. ChemMedChem, 2019, 14, 1537-1546.	1.6	19
16	Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. Future Medicinal Chemistry, 2019, 11, 1953-1977.	1.1	16
17	Synthetic organic chemistry driven by artificial intelligence. Nature Reviews Chemistry, 2019, 3, 589-604.	13.8	173
18	Phenotypic Effects of Wild-Type and Mutant SOD1 Expression in N9 Murine Microglia at Steady State, Inflammatory and Immunomodulatory Conditions. Frontiers in Cellular Neuroscience, 2019, 13, 109.	1.8	36

#	Article	IF	Citations
19	Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability. European Journal of Medicinal Chemistry, 2019, 172, 16-25.	2.6	6
20	Bioactive Quinolactacins and Structurally Related Pyrroloquinolones. Studies in Natural Products Chemistry, 2019, , 433-453.	0.8	3
21	An Overview of Drug Resistance in Protozoal Diseases. International Journal of Molecular Sciences, 2019, 20, 5748.	1.8	109
22	Design of Modular Gâ€quadruplex Ligands. ChemMedChem, 2018, 13, 869-893.	1.6	97
23	Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. European Journal of Medicinal Chemistry, 2018, 150, 525-545.	2.6	92
24	Endoperoxide-8-aminoquinoline hybrids as dual-stage antimalarial agents with enhanced metabolic stability. European Journal of Medicinal Chemistry, 2018, 149, 69-78.	2.6	30
25	Starch nanocapsules containing a novel neutrophil elastase inhibitor with improved pharmaceutical performance. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 1-11.	2.0	38
26	Diazaborines as New Inhibitors of Human Neutrophil Elastase. ACS Omega, 2018, 3, 7418-7423.	1.6	38
27	Spirotriazoline oxindoles: A novel chemical scaffold with inÂvitro anticancer properties. European Journal of Medicinal Chemistry, 2017, 140, 494-509.	2.6	27
28	Dipeptidyl Vinyl Sulfone as a Novel Chemical Tool to Inhibit HMGB1/NLRP3-Inflammasome and Inflamma-miRs in AÎ²-Mediated Microglial Inflammation. ACS Chemical Neuroscience, 2017, 8, 89-99.	1.7	38
29	Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?. ACS Chemical Neuroscience, 2017, 8, 50-59.	1.7	16
30	Chemical Variations on the p53 Reactivation Theme. Pharmaceuticals, 2016, 9, 25.	1.7	28
31	Clickable 4â€Oxoâ€Î²â€lactamâ€Based Selective Probing for Human Neutrophil Elastase Related Proteomes. ChemMedChem, 2016, 11, 2037-2042.	1.6	24
32	Probing the Azaaurone Scaffold against the Hepatic and Erythrocytic Stages of Malaria Parasites. ChemMedChem, 2016, 11, 2194-2204.	1.6	23
33	Novel squaramides with in vitro liver stage antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2016, 24, 1786-1792.	1.4	17
34	Spirooxadiazoline oxindoles with promising in vitro antitumor activities. MedChemComm, 2016, 7, 420-425.	3.5	24
35	The Cytotoxic Bile Acid DCA Modulates Apoptotic Signalling through Alteration of Mitochondrial Membrane Properties. Biophysical Journal, 2015, 108, 242a.	0.2	1
36	Stabilization of porcine pancreatic elastase crystals by glutaraldehyde cross-linking. Acta Crystallographica Section F, Structural Biology Communications, 2015, 71, 1346-1351.	0.4	7

#	Article	IF	Citations
37	Enantiopure Indolizinoindolones with in vitro Activity against Bloodâ€•and Liverâ€Stage Malaria Parasites. ChemMedChem, 2015, 10, 2080-2089.	1.6	30
38	1.2 Designing Covalent Inhibitors: A Medicinal Chemistry Challenge. , 2015, , 44-60.		2
39	A unified approach toward the rational design of selective low nanomolar human neutrophil elastase inhibitors. RSC Advances, 2015, 5, 51717-51721.	1.7	4
40	Discovery of C-shaped aurone human neutrophil elastase inhibitors. MedChemComm, 2015, 6, 1508-1512.	3.5	3
41	N10,N11-di-alkylamine indolo[3,2-b]quinolines as hemozoin inhibitors: Design, synthesis and antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2015, 23, 1530-1539.	1.4	15
42	Activity-based probes as molecular tools for biomarker discovery. MedChemComm, 2015, 6, 536-546.	3.5	8
43	Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype. European Journal of Medicinal Chemistry, 2015, 102, 320-333.	2.6	31
44	From hybrid compounds to targeted drug delivery in antimalarial therapy. Bioorganic and Medicinal Chemistry, 2015, 23, 5120-5130.	1.4	38
45	KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines. Scientific Reports, 2015, 5, 9696.	1.6	74
46	Targeting the Erythrocytic and Liver Stages of Malaria Parasites with sâ€TriazineâEBased Hybrids. ChemMedChem, 2015, 10, 883-890.	1.6	10
47	Indolo[3,2â€c]quinoline Gâ€Quadruplex Stabilizers: a Structural Analysis of Binding to the Human Telomeric Gâ€Quadruplex. ChemMedChem, 2015, 10, 836-849.	1.6	24
48	Deoxycholic acid modulates cell death signaling through changes in mitochondrial membrane properties. Journal of Lipid Research, 2015, 56, 2158-2171.	2.0	36
49	Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives. PLoS ONE, 2015, 10, e0126891.	1.1	41
50	Probing the aurone scaffold against Plasmodium falciparum: Design, synthesis and antimalarial activity. European Journal of Medicinal Chemistry, 2014, 80, 523-534.	2.6	64
51	Tetraoxaneâ€“Pyrimidine Nitrile Hybrids as Dual Stage Antimalarials. Journal of Medicinal Chemistry, 2014, 57, 4916-4923.	2.9	43
52	Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents. Bioorganic and Medicinal Chemistry, 2014, 22, 577-584.	1.4	56
53	Antiplasmodial Drugs in the Gas Phase: A CID and DFT Study of Quinolon-4(1H)-Imine Derivatives. Journal of the American Society for Mass Spectrometry, 2014, 25, 1650-1661.	1.2	2
54	Bis-alkylamine Indolo[3,2-b]quinolines as Hemozoin Ligands: Implications for Antimalarial Cytostatic and Cytocidal Activities. Journal of Medicinal Chemistry, 2014, 57, 3295-3313.	2.9	20

#	Article	IF	Citations
55	Analytical profiles of â€œlegal highsâ€•containing cathinones available in the area of Lisbon, Portugal. Forensic Science International, 2014, 244, 102-110.	1.3	16
56	Novel Endoperoxide-Based Transmission-Blocking Antimalarials with Liver- and Blood-Schizontocidal Activities. ACS Medicinal Chemistry Letters, 2014, 5, 108-112.	1.3	40
57	P116 INTERACTION OF APOPTOTIC AND CYTOPROTECTIVE BILE ACIDS WITH BIOMEMBRANES. Journal of Hepatology, 2014, 60, S105.	1.8	0
58	Targeting COPD: advances on lowâ€•molecularâ€•weight inhibitors of human neutrophil elastase. Medicinal Research Reviews, 2013, 33, E73-101.	5.0	84
59	Exploring the Molecular Basis of Q_obc₁ Complex Inhibitors Activity to Find Novel Antimalarials Hits. Molecular Informatics, 2013, 32, 659-670.	1.4	11
60	An Endoperoxideâ€Based Hybrid Approach to Deliver Falcipain Inhibitors Inside Malaria Parasites. ChemMedChem, 2013, 8, 1528-1536.	1.6	32
61	Synthesis, Gâ€Quadruplex Stabilisation, Docking Studies, and Effect on Cancer Cells of Indolo[3,2â€‹b]quinolines with One, Two, or Three Basic Side Chains. ChemMedChem, 2013, 8, 1648-1661.	1.6	39
62	Novel anti-Plasmodial hits identified by virtual screening of the ZINC database. Journal of Computer-Aided Molecular Design, 2013, 27, 859-871.	1.3	18
63	Squaric acid/4-aminoquinoline conjugates: Novel potent antiplasmodial agents. European Journal of Medicinal Chemistry, 2013, 69, 365-372.	2.6	21
64	Structural Optimization of Quinolon-4(1H)-imines as Dual-Stage Antimalarials: Toward Increased Potency and Metabolic Stability. Journal of Medicinal Chemistry, 2013, 56, 7679-7690.	2.9	14
65	The Apoptotic Bile Acid DCA has Preference for Association to Liquid Disordered Lipid Domains and Inhibits the Rigidifying Effect of Cholesterol in Membranes. Biophysical Journal, 2013, 104, 586a.	0.2	0
66	Synthetic Condensed 1,4-naphthoquinone Derivative Shifts Neural Stem Cell Differentiation by Regulating Redox State. Molecular Neurobiology, 2013, 47, 313-324.	1.9	21
67	Five-membered iminocyclitol Î±-glucosidase inhibitors: Synthetic, biological screening and in silico studies. Bioorganic and Medicinal Chemistry, 2013, 21, 1911-1917.	1.4	51
68	Quinolin-4(1H)-imines are Potent Antiplasmodial Drugs Targeting the Liver Stage of Malaria. Journal of Medicinal Chemistry, 2013, 56, 4811-4815.	2.9	21
69	Discovery of new heterocycles with activity against human neutrophile elastase based on a boron promoted one-pot assembly reaction. Organic and Biomolecular Chemistry, 2013, 11, 4465.	1.5	31
70	Cytotoxic bile acids, but not cytoprotective species, inhibit the ordering effect of cholesterol in model membranes at physiologically active concentrations. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 2152-2163.	1.4	36
71	Optimization of O₃-Acyl Kojic Acid Derivatives as Potent and Selective Human Neutrophil Elastase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 9802-9806.	2.9	26
72	Flavones as isosteres of 4(1H)-quinolones: Discovery of ligand efficient and dual stage antimalarial lead compounds. European Journal of Medicinal Chemistry, 2013, 69, 872-880.	2.6	13

#	Article	IF	Citations
73	Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2838-47.	3.3	73
74	Novel Potent Metallocenes against Liver Stage Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 1564-1570.	1.4	32
75	Comparative Analysis of In Vitro Rat Liver Metabolism of the Antimalarial Primaquine and a Derived Imidazoquine. Drug Metabolism Letters, 2012, 6, 15-25.	0.5	4
76	Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug. Journal of Infectious Diseases, 2012, 205, 1278-1286.	1.9	97
77	Four-Component Assembly of Chiral Nâ€“B Heterocycles with a Natural Product-Like Framework. Organic Letters, 2012, 14, 988-991.	2.4	22
78	Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6256-6260.	1.0	13
79	Targeting the Liver Stage of Malaria Parasites: A Yet Unmet Goal. Journal of Medicinal Chemistry, 2012, 55, 995-1012.	2.9	73
80	Comparative in vitro and in vivo antimalarial activity of the indole alkaloids ellipticine, olivacine, cryptolepine and a synthetic cryptolepine analog. Phytomedicine, 2012, 20, 71-76.	2.3	51
81	Peptidomimetic and Organometallic Derivatives of Primaquine Active against Leishmania infantum. Antimicrobial Agents and Chemotherapy, 2012, 56, 5774-5781.	1.4	30
82	Structure based virtual screening for discovery of novel human neutrophil elastase inhibitors. MedChemComm, 2012, 3, 1299.	3.5	15
83	Squaric acid: a valuable scaffold for developing antimalarials?. MedChemComm, 2012, 3, 489.	3.5	34
84	Microwave-Assisted Wittig Reaction of Semistabilized Nitro-Substituted Benzyltriphenyl-Phosphorous Ylides with Aldehydes in Phase-Transfer Conditions. Synthetic Communications, 2012, 42, 747-755.	1.1	5
85	¹H NMR spectroscopic identification of protonable sites in cryptolepines with Câ€11 substituents containing two amino functionalities. Magnetic Resonance in Chemistry, 2012, 50, 216-220.	1.1	5
86	A carbamate-based approach to primaquine prodrugs: Antimalarial activity, chemical stability and enzymatic activation. Bioorganic and Medicinal Chemistry, 2012, 20, 886-892.	1.4	23
87	N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3993-3997.	1.0	12
88	Efficient synthesis of spiroisoxazoline oxindoles. Tetrahedron Letters, 2012, 53, 281-284.	0.7	31
89	Characterizing the Dynamics and Ligand-Specific Interactions in the Human Leukocyte Elastase through Molecular Dynamics Simulations. Journal of Chemical Information and Modeling, 2011, 51, 1690-1702.	2.5	8
90	Incorporation of Basic Side Chains into Cryptolepine Scaffold: Structureâ^'Antimalarial Activity Relationships and Mechanistic Studies. Journal of Medicinal Chemistry, 2011, 54, 734-750.	2.9	57

#	Article	IF	Citations
91	Identification of new antimalarial leads by use of virtual screening against cytochrome bc1. Bioorganic and Medicinal Chemistry, 2011, 19, 6302-6308.	1.4	10
92	Aza vinyl sulfones: Synthesis and evaluation as antiplasmodial agents. Bioorganic and Medicinal Chemistry, 2011, 19, 7635-7642.	1.4	24
93	A quantum mechanical study of novel potential inhibitors of cytochrome bc₁ as antimalarial compounds. International Journal of Quantum Chemistry, 2011, 111, 1196-1207.	1.0	16
94	Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials. European Journal of Medicinal Chemistry, 2011, 46, 927-933.	2.6	33
95	Aspartic vinyl sulfones: Inhibitors of a caspase-3-dependent pathway. European Journal of Medicinal Chemistry, 2011, 46, 2141-2146.	2.6	25
96	New hope in the fight against malaria?. Future Medicinal Chemistry, 2011, 3, 1-3.	1.1	31
97	Design and Evaluation of Primaquine-Artemisinin Hybrids as a Multistage Antimalarial Strategy. Antimicrobial Agents and Chemotherapy, 2011, 55, 4698-4706.	1.4	65
98	Synthesis, stability, biochemical and pharmacokinetic properties of a new potent and selective 4-oxo-Î²-lactam inhibitor of human leukocyte elastase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 169-175.	2.5	9
99	Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. AÂstructureâ€“activity study. European Journal of Medicinal Chemistry, 2010, 45, 3858-3863.	2.6	34
100	Effect of Synthesized Inhibitors on Babesipain-1, a New Cysteine Protease from the Bovine Piroplasm Babesia Bigemina. Transboundary and Emerging Diseases, 2010, 57, 68-69.	1.3	9
101	Reaction of naphthoquinones with substituted nitromethanes. Facile synthesis and antifungal activity of naphtho[2,3-d]isoxazole-4,9-diones. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 193-195.	1.0	94
102	Bis-alkylamine quindolone derivatives as new antimalarial leads. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5634-5637.	1.0	22
103	C-11 diamino cryptolepine derivatives NSC748392, NSC748393, and NSC748394: Anticancer profile and G-quadruplex stabilization. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7042-7045.	1.0	26
104	Inhibitors of the Mitochondrial Electron Transport Chain and de novo Pyrimidine Biosynthesis as Antimalarials: The Present Status. Current Medicinal Chemistry, 2010, 17, 929-956.	1.2	43
105	Cell Death Targets and Potential Modulators in Alzheimers Disease. Current Pharmaceutical Design, 2010, 16, 2851-2864.	0.9	36
106	4-Oxo-Î²-lactams (Azetidine-2,4-diones) Are Potent and Selective Inhibitors of Human Leukocyte Elastase. Journal of Medicinal Chemistry, 2010, 53, 241-253.	2.9	43
107	Endoperoxide Carbonyl Falcipain 2/3 Inhibitor Hybrids: Toward Combination Chemotherapy of Malaria through a Single Chemical Entity. Journal of Medicinal Chemistry, 2010, 53, 8202-8206.	2.9	35
108	Indoloquinolines as Scaffolds for Drug Discovery. Current Medicinal Chemistry, 2010, 17, 2348-2370.	1.2	160

#	Article	IF	Citations
109	PRIMACENES: novel non-cytotoxic primaquine-ferrocene conjugates with anti-Pneumocystis carinii activity. MedChemComm, 2010, 1, 199.	3.5	25
110	Naphtho[2,3-d]isoxazole-4,9-dione-3-carboxylates: Potent, non-cytotoxic, antiapoptotic agents. Chemico-Biological Interactions, 2009, 180, 175-182.	1.7	10
111	Dopamine- and tyramine-based derivatives of triazenes: Activation by tyrosinase and implications for prodrug design. European Journal of Medicinal Chemistry, 2009, 44, 3228-3234.	2.6	18
112	Anti-tumoral activity of imidazoquines, a new class of antimalarials derived from primaquine. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6914-6917.	1.0	17
113	Structureâ€“activity relationships for dipeptide prodrugs of acyclovir: Implications for prodrug design. European Journal of Medicinal Chemistry, 2009, 44, 2339-2346.	2.6	24
114	Primaquine revisited six decades after its discovery. European Journal of Medicinal Chemistry, 2009, 44, 937-953.	2.6	300
115	Primaquine dipeptide derivatives bearing an imidazolidin-4-one moiety at the N-terminus as potential antimalarial prodrugs. European Journal of Medicinal Chemistry, 2009, 44, 2506-2516.	2.6	27
116	Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: Design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3229-3232.	1.0	49
117	Design, synthesis and structureâ€“activity relationships of (1H-pyridin-4-ylidene)amines as potential antimalarials. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3476-3480.	1.0	29
118	Imidazoquines as Antimalarial and Antipneumocystis Agents. Journal of Medicinal Chemistry, 2009, 52, 7800-7807.	2.9	35
119	Electrospray Ionization Mass Spectrometry as a Valuable Tool in the Characterization of Novel Primaquine Peptidomimetic Derivatives. European Journal of Mass Spectrometry, 2009, 15, 627-640.	0.5	5
120	Bis{(E)-3-[(diethylmethylammonio)methyl]-N-[3-(N,N-dimethylsulfamoyl)-1-methylpyridin-4-ylidene]-4-metho tetraiodide pentahydrate. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o283-o284.	0.2	4
121	Electrospray ionization-ion trap mass spectrometry study of PQAAPro and PQProAA mimetic derivatives of the antimalarial primaquine. Journal of the American Society for Mass Spectrometry, 2008, 19, 1476-1490.	1.2	8
122	Dipeptide Derivatives of AZT: Synthesis, Chemical Stability, Activation in Human Plasma, hPEPT1 Affinity, and Antiviral Activity. ChemMedChem, 2008, 3, 970-978.	1.6	18
123	Unanticipated Acyloxymethylation of Sumatriptan Indole Nitrogen Atom and its Implications in Prodrug Design. Archiv Der Pharmazie, 2008, 341, 344-350.	2.1	2
124	Anti-Pneumocystis carinii and antiplasmodial activities of primaquine-derived imidazolidin-4-ones. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 485-488.	1.0	29
125	Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: Synthesis, antiplasmodial activity, and cytotoxicity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1378-1381.	1.0	45
126	Amino acids as selective acylating agents: regioselective N1-acylation of imidazolidin-4-one derivatives of the antimalarial drug primaquine. Tetrahedron, 2008, 64, 11144-11149.	1.0	12

#	Article	IF	Citations
127	Imidazolidin-4-one peptidomimetic derivatives of primaquine: Synthesis and antimalarial activity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4150-4153.	1.0	31
128	Characterization of primaquine imidazolidin-4-ones with antimalarial activity by electrospray ionization-ion trap mass spectrometry. International Journal of Mass Spectrometry, 2008, 270, 81-93.	0.7	10
129	Azetidine-2,4-diones (4-Oxo-Î²-lactams) as Scaffolds for Designing Elastase Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 1783-1790.	2.9	31
130	Malaria Combination Therapies: Advantages and Shortcomings. Mini-Reviews in Medicinal Chemistry, 2008, 8, 201-212.	1.1	37
131	Crystallization and Preliminary Diffraction Studies of Porcine Pancreatic Elastase in Complex with a Novel Inhibitor. Protein and Peptide Letters, 2007, 14, 93-95.	0.4	5
132	Michael Acceptors as Cysteine Protease Inhibitors. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1040-1050.	1.1	130
133	The efficiency of C-4 substituents in activating the Î²-lactam scaffold towards serine proteases and hydroxide ion. Organic and Biomolecular Chemistry, 2007, 5, 2617.	1.5	18
134	Unanticipated Stereoselectivity in the Reaction of Primaquine Î±-Aminoamides with Substituted Benzaldehydes:â€‰ A Computational and Experimental Study. Journal of Organic Chemistry, 2007, 72, 4189-4197.	1.7	22
135	Cyclization-activated Prodrugs. Molecules, 2007, 12, 2484-2506.	1.7	50
136	Aminocarbonyloxymethyl Ester Prodrugs of Flufenamic Acid and Diclofenac: Suppressing the Rearrangement Pathway in Aqueous Media. Archiv Der Pharmazie, 2007, 340, 32-40.	2.1	17
137	The 1,4-naphthoquinone scaffold in the design of cysteine protease inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 5340-5350.	1.4	33
138	The Bsmoc group as a novel scaffold for the design of irreversible inhibitors of cysteine proteases. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2738-2741.	1.0	9
139	Dipeptide vinyl sultams: Synthesis via the Wittigâ€“Horner reaction and activity against papain, falcipain-2 and Plasmodium falciparum. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4115-4119.	1.0	66
140	Reactivity of imidazolidin-4-one derivatives of primaquine: implications for prodrug design. Tetrahedron, 2006, 62, 9883-9891.	1.0	28
141	Cyclization-activated prodrugs. Synthesis, reactivity and toxicity of dipeptide esters of paracetamol. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1595-1598.	1.0	32
142	Amidomethylation of Amodiaquine: Antimalarial N-Mannich Base Derivatives.. ChemInform, 2005, 36, no.	0.1	0
143	Design, Synthesis, and Enzymatic Evaluation ofN1-Acyloxyalkyl-andN1-Oxazolidin-2,4-dion-5-yl-Substituted Î²-lactams as Novel Inhibitors of Human Leukocyte Elastase. Journal of Medicinal Chemistry, 2005, 48, 4861-4870.	2.9	33
144	Imidazolidin-4-one Derivatives of Primaquine as Novel Transmission-Blocking Antimalarials. Journal of Medicinal Chemistry, 2005, 48, 888-892.	2.9	78

#	Article	IF	Citations
145	Synthesis of imidazolidin-4-one and 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione derivatives of primaquine: scope and limitations. Tetrahedron, 2004, 60, 5551-5562.	1.0	68
146	Synthesis of Imidazolidin-4-one and 1H-Imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione Derivatives of Primaquine: Scope and Limitations.. ChemInform, 2004, 35, no.	0.1	0
147	Amidomethylation of amodiaquine: antimalarial N-Mannich base derivatives. Tetrahedron Letters, 2004, 45, 7663-7666.	0.7	49
148	Kinetics and Mechanism of Hydrolysis ofN-Acyloxymethyl Derivatives of Azetidin-2-one. Journal of Organic Chemistry, 2004, 69, 3359-3367.	1.7	17
149	Novel 3+1 mixed-ligand Technetium-99m complexes carrying dipeptides as monodentate ligands. Nuclear Medicine and Biology, 2004, 31, 139-146.	0.3	3
150	Amino acids as selective sulfonamide acylating agents. Tetrahedron, 2003, 59, 7473-7480.	1.0	11
151	Improved Synthesis of Amino Acid and Dipeptide Chloromethyl Esters Using Bromochloromethane. Synthetic Communications, 2003, 33, 1683-1693.	1.1	9
152	Synthesis, Stability and In Vitro Dermal Evaluation of Aminocarbonyloxymethyl Esters as Prodrugs of Carboxylic Acid Agents. Bioorganic and Medicinal Chemistry, 2002, 10, 809-816.	1.4	17
153	Kinetics and mechanism of hydrolysis of N-amidomethylsulfonamides. Perkin Transactions II RSC, 2001, , 749-753.	1.1	11
154	Design, Synthesis and Stability of N-Acyloxymethyl- and N-Aminocarbonyloxymethyl-2-azetidinones as Human Leukocyte Elastase Inhibitors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1065-1068.	1.0	52
155	Acyloxymethyl as a drug protecting group. Part 6. Bioorganic and Medicinal Chemistry, 2000, 8, 707-716.	1.4	19
156	Acyloxymethyl as a drug protecting group. Part 7: Tertiary sulfonamidomethyl ester prodrugs of benzylpenicillin: chemical hydrolysis and anti-bacterial activity. Bioorganic and Medicinal Chemistry, 2000, 8, 1629-1636.	1.4	5
157	Dipeptide derivatives of primaquine as transmission-blocking antimalarials: effect of aliphatic side-chain acylation on the gametocytocidal activity and on the formation of carboxyprimaquine in rat liver homogenates. Pharmaceutical Research, 1999, 16, 949-955.	1.7	34
158	Cleavage of tertiary amidomethyl ester prodrugs of carboxylic acids by rat liver homogenates. European Journal of Pharmaceutical Sciences, 1999, 9, 201-205.	1.9	7
159	Metabolism of primaquine by liver homogenate fractions. Experimental and Toxicologic Pathology, 1999, 51, 299-303.	2.1	83
160	Acyloxymethyl as a drug protecting group. Part 5.1 Kinetics and mechanism of the hydrolysis of tertiary N-acyloxymethylsulfonamides. Journal of the Chemical Society Perkin Transactions II, 1999, , 431-440.	0.9	10
161	Phthalimidomethyl as a drug Pro-moiety. Probing its reactivity. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 955-958.	1.0	7
162	Acyloxymethyl as a drug protecting group: Part 4. The hydrolysis of tertiary amidomethyl ester prodrugs of carboxylic acid agents. Pharmaceutical Research, 1997, 14, 1634-1639.	1.7	32

#	Article	IF	Citations
163	Acyloxymethyl as a drug protecting group. Part 3. Tertiary O-amidomethyl esters of penicillin G: chemical hydrolysis and anti-bacterial activity. Pharmaceutical Research, 1996, 13, 70-75.	1.7	17
164	Acyloxymethyl as a drug protecting group. Synthesis and reactivity of N-acyloxymethylsulfonamide prodrugs. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 937-940.	1.0	7
165	A new direct synthesis of tertiary N-acyloxymethylamide prodrugs of carboxylic acid drugs. Tetrahedron Letters, 1994, 35, 7107-7110.	0.7	21
166	Triazene drug metabolites. Part 11. Synthesis of S-cysteinyl and related derivatives of N-hydroxymethyltriazenes. Journal of the Chemical Society Perkin Transactions 1, 1991, , 3241.	0.9	5
167	Triazene drug metabolites. Part 10. Metal-ion catalysed decomposition of monoalkyltriazenes in ethanol solutions. Journal of the Chemical Society Perkin Transactions II, 1991, , 81.	0.9	6
168	Acyloxymethyl as a drug protecting group. Kinetics and mechanism of the hydrolysis of N-acyloxymethylbenzamides. Journal of the Chemical Society Perkin Transactions II, 1991, , 563.	0.9	20
169	Synthesis of S-cysteinyl, S(N-acetylcysteinyl) and S-glutathionyl conjugates op N-hydroxymethyltriazenes. Tetrahedron Letters, 1988, 29, 2707-2710.	0.7	6
170	Triazene drug metabolites. Part 4. Kinetics and mechanism of the decomposition of 1-aryl-3-benzoyloxymethyl-3-methyltriazenes in mixed aqueousâ€“organic solvents. Journal of the Chemical Society Perkin Transactions II, 1987, , 1503-1508.	0.9	8
171	Alkylating Agents. , 0, , 133-158.		11
172	Contribution of Mass Spectrometry to the Study of Antimalarial Agents. , 0, , .		2